
CEP-32496
CAS No. 1188910-76-0
CEP-32496( —— )
Catalog No. M10648 CAS No. 1188910-76-0
CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 49 | In Stock |
![]() ![]() |
5MG | 80 | In Stock |
![]() ![]() |
10MG | 120 | In Stock |
![]() ![]() |
25MG | 219 | In Stock |
![]() ![]() |
50MG | 357 | In Stock |
![]() ![]() |
100MG | 534 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameCEP-32496
-
NoteResearch use only, not for human use.
-
Brief DescriptionCEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM.
-
DescriptionCEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2. Phase 1/2.(In Vitro):Agerafenib (CEP-32496) exhibits high potency against several BRAFV600E-dependent cell lines and selective cytotoxicity for tumor cell lines expressing mutant BRAFV600E versus those containing wild-type BRAF. Agerafenib exhibits potent binding (BRAFV600E Kd=14 nM) and cellular activity (pMEK IC50=82 nM and A375 proliferation IC50=78 nM), with activity in the proliferation assay. Agerafenib also exhibits a favorable CYP450 inhibition profile, with measured IC50 values greater than 10 μM versus the CYP1A2, CYP2C9, CYP2D6, and CYP3A4 isoforms and an IC50=3.4 μM versus CYP2C19. (In Vivo):Oral administration of Agerafenib (CEP-32496) to Colo-205 tumor xenograft-bearing mice results in significant inhibition of pMEK in tumor cell lysates. For instance, a single 30 mg/kg (po) dose of Agerafenib leads to a 50 and 75% inhibition of normalized pMEK in tumor lysates at the 2 and 6 h postdose time point, respectively (p<0.03), while a 55 mg/kg (po) dose resulted in a 75% to 57% (p<0.03) inhibition of pMEK at 2 through 10 h post administration, with normalization to baseline by 24 h. Agerafenib exhibits an exceptional PK profile in mouse, dog, and cynomolgus monkey. Administration of Agerafenib to beagle dogs (single dose of 1 mg/kg iv and 10 mg/kg po) results in low clearance (CL=5.0 (mL/min)/kg) and excellent bioavailability (%F=100). Similarly, in cynomolgus monkey, the administration of Agerafenib (single dose of 1 mg/kg iv and 10 mg/kg po) leads to high oral exposure due to low clearance (CL=6.7 mL/min/kg) and excellent bioavailability (%F=100).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetBcr-Abl
-
RecptorAbl1| c-Kit| RET| PDGFRβ| Lck
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1188910-76-0
-
Formula Weight517.46
-
Molecular FormulaC24H22F3N5O5
-
Purity>98% (HPLC)
-
SolubilityDMSO: 9 mg/mL (17.39 mM)
-
SMILESCOC1=C(OC)C=C2C(OC3=CC=CC(NC(=O)NC4=NOC(=C4)C(C)(C)C(F)(F)F)=C3)=NC=NC2=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Rowbottom MW, et al. J Med Chem, 2012, 55(3), 1082-1105.
molnova catalog



related products
-
Resiquimod
Resiquimod is an imidazoquinoline amine and Toll-like receptor (TLR) agonist with potential immune response modifying activity.
-
Solanesol
Phytochemical present in tobacco leaf. Starting material for synthesis of co-enzyme Q10. Exhibits antiulcer activity.
-
PP1
PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.